Global Pulmonary Arterial Hypertension Market Size, Share & Trends Analysis Report By Drug Class (Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin & Prostacyclin Analogs, and SGC Stimulators), By Type (Branded and Generics), By Route Of Administration (Oral, Intravenous/ Subcutaneous, and Inhalational), and By Region and Forecast from 2022-2027
Global Pulmonary Arterial Hypertension Market
Global Pulmonary Arterial Hypertension Market was valued at USD 2.0 billion in 2021 which is expected to reach USD 7.0 billion by 2027, at a CAGR of 23.22 % from 2022-2027.
Pulmonary arterial hypertension is increased pulmonary arterial pressure and localized hypertension caused by a series of uncommon, potentially fatal disorders that can end in heart failure. The term "pulmonary hypertension" describes a specific form of high blood pressure that mostly affects the right side of the heart and the arteries in the lungs. It is characterized by capillaries and arteries that are clogged and narrowed. PDE-5 inhibitors, prostacyclin and its analogs, SGC stimulators, and endothelin receptor antagonists (ERAS) are some of the medications used to treat pulmonary arterial hypertension.
Market Driver
The high prevalence and incidence of the condition, together with its severity and threat to lifespan, will contribute to the rising demand for pulmonary arterial hypertension drugs, which is predicted to fuel market expansion throughout the forecast period. According to United Therapeutics, there are around 45,000 Americans who have pulmonary arterial hypertension. The American Lung Association claims that women between the ages of 30 and 60 are more likely than men to develop PAH. Between 15 to 20 percent of patients are thought to have heritable PAH, suggesting that the cause may be hereditary or idiopathic. Cirrhosis of the liver, connective tissue disorders, congenital cardiac defects, and infections including HIV and schistosomiasis are some other ailments connected to PAH.
The rise in the elderly has negative effects, some of which include pulmonary arterial hypertension-related problems. Technological developments are also steadily concentrating on the discovery of novel molecular pathways, which makes it feasible to build better treatments in the future.
Market Restraints
The medication molecule's patent expiration and its related adverse effects hinder the global pulmonary arterial hypertension market expansion. The development of the pulmonary arterial hypertension (PAH) market in the upcoming years would be further hampered by strict medication recommendations.
Market Segmentation
Global Pulmonary Arterial Hypertension Market is segmented into Drug Class such as Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin & Prostacyclin Analogs, and SGC Stimulators. Furthermore, the market is divided into Types such as Branded and Generics. Moreover, the market is segmented into Route Of Administration such as Oral, Intravenous/ Subcutaneous, and Inhalational.
Regional Analysis
Global Pulmonary Arterial Hypertension Market is segmented into five regions such as North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America is estimated to dominate the market during the forecast period due to the sophisticated healthcare systems in the United States and Canada, which make it easier to get cutting-edge treatments. The expansion of the market in this area is aided by improved awareness, a high diagnosis rate, and supportive government measures. The presence of important businesses and a well-planned reimbursement mechanism both support the expansion of the local market.
The market in Asia Pacific is anticipated to grow at the highest CAGR rate due to rising generic drug consumption, the presence of major pharmaceutical companies, and expanding healthcare.
Key Developments
In June 2022, Tyvaso DPI (treprostinil) inhalation powder was approved by the US Food and Drug Administration for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease to enhance exercise capacity.
In July 2022, The first patient entered the Phase II research for pulmonary arterial hypertension (PAH) using medication candidate CS1, according to an announcement from Cereno Scientific.
Key Players
Bayer AG, GlaxoSmithKline Plc, Gilead Sciences, Inc., Johnson & Johnson, Lupin Pharmaceuticals, Inc., Sandoz Inc. (Novartis), Sun Pharmaceutical Industries, Ltd., Teva Pharmaceutical Industries Ltd., United Therapeutics Corporation, and Viatris Inc. are just a few of the major players discussed in this study.
Market Taxonomy
By Drug Class
• Endothelin Receptor Antagonists (ERAs)
• PDE-5 Inhibitors
• Prostacyclin & Prostacyclin Analogs
• SGC Stimulators
By Type
• Branded
• Generics
By Route Of Administration
• Oral
• Intravenous/ Subcutaneous
• Inhalational
By Region
• North America
• Latin America
• Europe
• Asia Pacific
• Middle East & Africa
Global Pulmonary Arterial Hypertension Market TOC
1 Introduction
1.1 Objective of the Study
1.2 Market definition
1.3 Market Scope
2 Research Methodology
2.1 Data Mining
2.2 Validation
2.3 Primary Interviews
2.4 List of Data Sources
3 Executive Summary
4 Global Pulmonary Arterial Hypertension Market Outlook
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.2.4 Cumulative Impact due to recent Energy Crisis
4.2.5 Cumulative Impact due to nearing economic downturn
4.2.6 Post covid-19 world Supply & Demand conditions
4.2.7 Cumulative Impact of Russia-Ukraine Conflict
4.3 Porters Five Force Model
4.4 Value Chain Analysis
5 Global Pulmonary Arterial Hypertension Market, By Drug Class
5.1 Y-o-Y Growth Comparison, By Drug Class
5.2 Global Pulmonary Arterial Hypertension Market Share Analysis, By Drug Class
5.3 Global Pulmonary Arterial Hypertension Market Size and Forecast, By Drug Class
5.3.1 Endothelin Receptor Antagonists (ERAs
5.3.2. PDE-5 Inhibitors
5.3.3. Prostacyclin & Prostacyclin Analogs
5.3.4. SGC Stimulators
6 Global Pulmonary Arterial Hypertension Market, By Type
6.1 Y-o-Y Growth Comparison, By Type
6.2 Global Pulmonary Arterial Hypertension Market Share Analysis, By Type
6.3 Global Pulmonary Arterial Hypertension Market Size and Forecast, By Type
6.3.1 Branded
6.3.2 Generics
7 Global Pulmonary Arterial Hypertension Market, By Route Of Administration
7.1 Y-o-Y Growth Comparison, By Route Of Administration
7.2 Global Pulmonary Arterial Hypertension Market Share Analysis, By Route Of Administration
7.3 Global Pulmonary Arterial Hypertension Market Size and Forecast, By Route Of Administration
7.3.1 Oral
7.3.2. Intravenous/ Subcutaneous
7.3.3. Inhalational
8 Global Pulmonary Arterial Hypertension Market, By Region
8.1 Global Pulmonary Arterial Hypertension Market Share Analysis, By Region
8.2 Global Pulmonary Arterial Hypertension Market Share Analysis, By Region
8.3 Global Pulmonary Arterial Hypertension Market Size and Forecast, By Region
9 North America Pulmonary Arterial Hypertension Market Analysis and Forecast (2022-2027)
9.1 Introduction
9.2 North America Pulmonary Arterial Hypertension Market Share Analysis, By Drug Class
9.3 North America Pulmonary Arterial Hypertension Market Size and Forecast, By Type
9.4 North America Pulmonary Arterial Hypertension Market Size and Forecast, By Route Of Administration
9.5 North America Pulmonary Arterial Hypertension Market Size and Forecast, By Country
9.5.1 U.S.
9.5.2 Canada
9.5.3 Mexico
10 Europe Pulmonary Arterial Hypertension Market Analysis and Forecast (2022-2027)
10.1 Introduction
10.2 Europe Pulmonary Arterial Hypertension Market Share Analysis, By Drug Class
10.3 Europe Pulmonary Arterial Hypertension Market Size and Forecast, By Type
10.4 Europe Pulmonary Arterial Hypertension Market Size and Forecast, By Route Of Administration
10.5 Europe Pulmonary Arterial Hypertension Market Size and Forecast, By Country
10.5.1 Germany
10.5.2 France
10.5.3 UK
10.54. Rest of Europe
11 Asia Pacific Pulmonary Arterial Hypertension Market Analysis and Forecast (2022-2027)
11.1 Introduction
11.2 Asia Pacific Pulmonary Arterial Hypertension Market Share Analysis, By Drug Class
11.3 Asia Pacific Pulmonary Arterial Hypertension Market Size and Forecast, By Type
11.4 Asia Pacific Pulmonary Arterial Hypertension Market Size and Forecast, By Route Of Administration
11.5 Asia Pacific Pulmonary Arterial Hypertension Market Size and Forecast, By Country
11.5.1 China
11.5.2 Japan
11.5.3 India
11.5.4. Rest of Asia Pacific
12 Latin America Pulmonary Arterial Hypertension Market Analysis and Forecast (2022-2027)
12.1 Introduction
12.2 Latin America Pulmonary Arterial Hypertension Market Share Analysis, By Drug Class
12.3 Latin America Pulmonary Arterial Hypertension Market Size and Forecast, By Type
12.4 Latin America Pulmonary Arterial Hypertension Market Size and Forecast, By Route Of Administration
12.5 Latin America Pulmonary Arterial Hypertension Market Size and Forecast, Country
13 Middle East Pulmonary Arterial Hypertension Market Analysis and Forecast (2022-2027)
13.1 Introduction
13.2 Middle East Pulmonary Arterial Hypertension Market Share Analysis, By Drug Class
13.3 Middle East Pulmonary Arterial Hypertension Market Size and Forecast, By Type
13.4 Middle East Pulmonary Arterial Hypertension Market Size and Forecast, By Route Of Administration
13.5 Middle East Pulmonary Arterial Hypertension Market Size and Forecast, By Country
14 Competitive Analysis
14.1 Competition Dashboard
14.2 Market share Analysis of Top Vendors
14.3 Key Development Strategies
15 Company Profiles
15.1 Bayer AG
15.1.1 Overview
15.1.2 Offerings
15.1.3 Key Financials
15.1.4 Business Segment & Geographic Overview
15.1.5 Key Market Developments
15.1.6 Key Strategies
15.2. GlaxoSmithKline Plc
15.2.1 Overview
15.2.2 Offerings
15.2.3 Key Financials
15.2.4 Business Segment & Geographic Overview
15.2.5 Key Market Developments
15.2.6 Key Strategies
15.3. Gilead Sciences, Inc.
15.3.1 Overvie
15.3.2 Offerings
15.3.3 Key Financials
15.3.4 Business Segment & Geographic Overview
15.3.5 Key Market Developments
15.3.6 Key Strategies
15.4 Johnson & Johnson
15.4.1 Overview
15.4.2 Offerings
15.4.3 Key Financials
15.4.4 Business Segment & Geographic Overview
15.4.5 Key Market Developments
15.4.6 Key Strategies
15.5 Lupin Pharmaceuticals
15.5.1 Overview
15.5.2 Offerings
15.5.3 Key Financials
15.5.4 Business Segment & Geographic Overview
15.5.5 Key Market Developments
15.5.6 Key Strategies
15.6 Sandon Global, Inc.
15.6.1 Overview
15.6.2 Offerings
15.6.3 Key Financials
15.6.4 Business Segment & Geographic Overview
15.6.5 Key Market Developments
15.6.6 Key Strategies
15.7 Sandoz Inc. (Novartis)
15.7.1 Overview
15.7.2 Offerings
15.7.3 Key Financials
15.7.4 Business Segment & Geographic Overview
15.7.5 Key Market Developments
15.7.6 Key Strategies
15.8 Sun Pharmaceutical Industries, Ltd.
15.8.1 Overview
15.8.2 Offerings
15.8.3 Key Financials
15.8.4 Business Segment & Geographic Overview
15.8.5 Key Market Developments
15.8.6 Key Strategies
15.9 Teva Pharmaceutical Industries Ltd.
15.9.1 Overview
15.9.2 Offerings
15.9.3 Key Financials
15.9.4 Business Segment & Geographic Overview
15.9.5 Key Market Developments
15.9.6 Key Strategies
15.10 United Therapeutics Corporation
15.10.1 Overview
15.10.2 Offerings
15.10.3 Key Financials
15.10.4 Business Segment & Geographic Overview
15.10.5 Key Market Developments
15.10.6 Key Strategies
15.11 Viatris Inc.
15.11.1 Overview
15.11.2 Offerings
15.11.3 Key Financials
15.11.4 Business Segment & Geographic Overview
15.11.5 Key Market Developments
15.11.6 Key Strategies
